PASTORCZAK, Agata, Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ, Arpád KEREKES, Zdenka KŘENOVÁ, Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG a Jan LOEFFEN. Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders. Cancers. Basel: MDPI, 2022, roč. 14, č. 8, s. 1-23. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14082000.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders
Autoři PASTORCZAK, Agata (garant), Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ (203 Česká republika, domácí), Arpád KEREKES (703 Slovensko, domácí), Zdenka KŘENOVÁ (203 Česká republika, domácí), Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG a Jan LOEFFEN.
Vydání Cancers, Basel, MDPI, 2022, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200
Kód RIV RIV/00216224:14110/22:00128354
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/cancers14082000
UT WoS 000786061500001
Klíčová slova anglicky DNA repair disorder; Ataxia Telangiectasia; Nijmegen breakage syndrome; leukemia; lymphoma; clinical management
Štítky 14110114, 14110321, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 19. 2. 2024 10:51.
Anotace
Simple Summary Ataxia Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are the most common DNA repair disorders (DNARDs), characterized by an exceedingly high risk for developing hematological malignancies and poor outcomes. Clinical management of lymphoproliferative diseases in AT and NBS is complicated due to the competing challenges of delivery of optimal cancer treatment and management of excessive toxicities. AT and NBS are rare genetic entities in the general population, thus gaining extensive experience in treatment of these patients is difficult. Additionally, no treatment guidelines for lymphoproliferative diseases have been specifically designed for this group of patients as yet. In this review we formulate clinical recommendations, considering the most critical aspects related to the management of lymphoproliferative disorders in AT and NBS and we concisely present the current state of knowledge about the biology and outcomes of leukemia and lymphoma in these DNARDs. Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.
VytisknoutZobrazeno: 18. 7. 2024 15:43